Mouse anti Human CD13, conjugated with FITCCatalog number: 0132
Identification of human Monocytes and Granulocytes expressing the 150 kD M.W. surface antigen. CD13 is a membrane enzyme, Aminopeptidase N. Myeloid cells in regenerating bone marrow will have an increased expression of CD13 in comparison with normal bone marrow myeloid cells.
Synonyms: CD13 FITC
Immunogen: CD13=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c x C57BL16 hybrid mice immunized with KG-1a cell line.
Product Form: FITC
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide and 0.2% carrier protein
Purification Method: Protein A/G Chromatography
Concentration: Titered for flow cytometry
PBMC: Add10 µl of MAB/10^6 PBMC in 100 µl PBS. Mix gently and incubate for 15 minutes at 2º to 8ºC. Wash twice with PBS and analyze. WHOLE BLOOD: Add 10 µl of MAB/100 µl of whole blood. Mix gently and incubate for 15 minutes at room temperature (20ºC). Lyse the whole blood. Wash once with PBS and analyze. See instrument manufacturer’s instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
Functional Analysis: Flow Cytometry Staining
Product should be stored at 4-8ºC. DO NOT FREEZE
Product Stability: See expiration date on vial
Shipping Conditions: Room Temperature
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Induction of CD13 expression on fresh myeloid leukemia: correlation of CD13 expression with aminopeptidase-N activity. Razak K; Newland AC Leuk Res 1992 Jun-Jul;16(6-7):625-30. 2. Surface marker expression in acute myeloid leukemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4. 3. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Bassan R; Biondi A; Benvestito S; Tini ML; Abbate M; Viero P; Barbui T; Rambaldi A Cancer 1992 Jan 15;69(2):396-404. 4. Monocytes appearing repeatedly after chemotherapies had an identical rearrangement pattern of immunoglobulin with leukemic blasts in a patient with CD13+ acute lymphoblastic leukemia. Mizuki M; Tagawa S; Nojima J; Nakamura Y; Morita T; Yumura-Yagi K; Hara J; Kawa-Ha K; Kitani T Acta Haematol 1992;87(1-2):88-93.
Database Name: UniProt
Accession Number: P15144
Safety Datasheet(s) for this product:
Mouse anti Human CD13, conjugated with FITC
$181.00Add To Cart